Daily Ards Research Analysis
A network meta-analysis ranks corticosteroids and neuromuscular blocking agents for ARDS, suggesting dexamethasone improves ventilator-free days and vecuronium may reduce 28-day mortality, while inhaled nitric oxide shows little benefit. A nationwide Spanish cohort (93,192 MV-ARDS admissions) shows stabilized incidence, declining mortality, and rising costs, with distinct COVID-era shifts. An integrated CT/LUS-clinical nomogram in COVID-19 markedly improves mortality prediction over imaging alon
Summary
A network meta-analysis ranks corticosteroids and neuromuscular blocking agents for ARDS, suggesting dexamethasone improves ventilator-free days and vecuronium may reduce 28-day mortality, while inhaled nitric oxide shows little benefit. A nationwide Spanish cohort (93,192 MV-ARDS admissions) shows stabilized incidence, declining mortality, and rising costs, with distinct COVID-era shifts. An integrated CT/LUS-clinical nomogram in COVID-19 markedly improves mortality prediction over imaging alone.
Research Themes
- Therapeutic ranking of ARDS adjuncts (corticosteroids, NMBAs, iNO)
- Epidemiology and health economics of mechanically ventilated ARDS
- Multimodal prognostication integrating imaging and clinical data in COVID-19
Selected Articles
1. Comparative outcomes of corticosteroids, neuromuscular blocking agents, and inhaled nitric oxide in ARDS: a systematic review and network meta-analysis.
Across 26 trials (5,071 patients), vecuronium ranked best for reducing 28-day mortality, dexamethasone maximized 28-day ventilator-free days and had a favorable infection profile, and inhaled nitric oxide showed no significant benefit. Findings support corticosteroids and selective NMBAs as beneficial adjuncts in ARDS.
Impact: This PROSPERO-registered network meta-analysis clarifies comparative effectiveness among commonly used ARDS adjuncts, informing guideline updates and clinical decision-making.
Clinical Implications: Consider early dexamethasone to improve ventilator-free days and selective NMBA (e.g., vecuronium) in appropriate ARDS phenotypes; avoid routine iNO given lack of mortality benefit.
Key Findings
- Vecuronium bromide ranked highest for reducing 28-day mortality (SUCRA 96.6%; OR vs comparators 0.23–0.38).
- Dexamethasone increased ventilator-free days at 28 days versus conventional therapy and cisatracurium (MD ~3.4–3.6 days; SUCRA 93.2%).
- Methylprednisolone ranked highest for preventing ICU mortality (SUCRA 88.5%).
- Inhaled nitric oxide did not demonstrate significant beneficial effects and dexamethasone had a favorable infection-risk profile.
Methodological Strengths
- PROSPERO-registered, dual independent data extraction, and frequentist network meta-analysis with SUCRA ranking.
- Included 26 clinical trials (n=5,071) with multiple clinically relevant outcomes (28-day mortality, ventilator-free days, ICU mortality, infections).
Limitations
- Heterogeneity in trial designs, dosing regimens, and ARDS populations may affect transitivity assumptions.
- Some comparisons had wide confidence intervals; lack of patient-level data limits subgroup analyses.
Future Directions: Head-to-head RCTs comparing NMBA agents and standardized steroid regimens; individual patient data meta-analysis to define phenotype-specific benefits.
OBJECTIVES: Acute respiratory distress syndrome (ARDS) is associated with high rates of morbidity and mortality. However, the evidence regarding the effectiveness of commonly used treatments, including corticosteroids, neuromuscular blocking agents (NMBAs), and inhaled nitric oxide (iNO), remains uncertain. Therefore, this study aimed to compare and rank these three treatments to identify the most effective option. DATA SOURCES: We searched PubMed, Embase, Cochrane Library, and Web of Science for clinical trials from the earliest records to 1 May 2024. STUDY SELECTION AND DATA EXTRACTION: Clinical trials evaluating three interventions compared with the control group for ARDS were included, with restrictions on any language. Data were extracted by two independent reviewers. Frequentist network meta-analysis (NMA) was performed to identify the most effective intervention, and treatments were ranked using the surface under the cumulative ranking (SUCRA) curve. The primary outcome was 28-day mortality, while secondary outcomes included ventilator-free days up to 28 days, ICU mortality, in-hospital mortality, and the incidence of new infection events. DATA SYNTHESIS: Data from 26 clinical trials encompassing 5,071 patients were analyzed. Vecuronium bromide was the most effective strategy for reducing 28-day mortality compared to conventional treatment, iNO, methylprednisolone, and placebo (OR 0.38, 95% CI 0.15-1.00, and OR 0.30, 95% CI 0.10-0.85 and OR 0.25, 95% CI 0.08-0.74 and OR 0.23, 95% CI 0.08-0.65; SUCRA: 96.6%). Dexamethasone was identified as the most effective treatment option for increasing ventilator-free days at 28 days compared to conventional therapy and cisatracurium (MD 3.60, 95% CI 1.77-5.43, and MD 3.40, 95% CI 0.87-5.92; SUCRA: 93.2%). Methylprednisolone demonstrated the highest effectiveness for preventing ICU mortality (SUCRA: 88.5%). Although dexamethasone, cisatracurium, conventional therapy, methylprednisolone, and iNO treatment did not show significant superiority in reducing in-hospital mortality, dexamethasone showed the highest probability of being the most effective treatment option (SUCRA: 79.7%). Furthermore, dexamethasone treatment showed the highest safety in reducing the incidence of new infection events compared with placebo and iNO (OR 0.61, 95% CI 0.42-0.88, and OR 0.33, 95% CI 0.19-0.58; SUCRA: 91.8%). CONCLUSION: This NMA suggests that corticosteroids may provide benefits to patients with ARDS. While the application of NMBAs may reduce 28-day mortality, iNO did not demonstrate a significant beneficial effect as a therapeutic measure. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42022333165 https://www.crd.york.ac.uk/PROSPERO/.
2. Epidemiological trends of mechanically ventilated acute respiratory distress syndrome in the twenty-first century: a nationwide, population-based retrospective study.
In 93,192 MV-ARDS hospitalizations across Spain (2000–2022), incidence stabilized after peaking in 2021, mortality declined overall, and costs per patient increased and stabilized around €30–40k. During COVID-19, hospital stays lengthened while mortality decreased, with more obesity/diabetes and fungal/viral etiologies.
Impact: This is Europe’s largest MV-ARDS epidemiology study, providing contemporary incidence, outcome, and economic trends that inform health policy and resource planning.
Clinical Implications: Benchmarking MV-ARDS incidence, mortality, and costs supports ICU capacity planning, ECMO/ventilation resource allocation, and prioritization of preventive strategies in high-risk populations.
Key Findings
- Analyzed 93,192 MV-ARDS admissions; incidence ranged 2.96–20.14 per 100,000 person-years, peaking in 2021.
- Hospital mortality ranged 38.0–55.0% with a declining trend over time.
- Cost per patient increased nearly fourfold, stabilizing around €30–40k after a 2011 peak (€42,812).
- During COVID-19, length of stay increased while mortality decreased; higher prevalence of obesity/diabetes and fungal/viral etiologies.
Methodological Strengths
- Nationwide, population-based dataset with ~99.5% coverage over 23 years.
- Large sample size enables robust trend analyses and economic assessments.
Limitations
- Retrospective administrative coding may misclassify ARDS severity and etiology.
- Lack of granular clinical variables limits causal inference and phenotype-specific insights.
Future Directions: Link administrative data with clinical registries for phenotype-level analyses; validate trends in other countries; assess drivers of cost and outcomes.
PURPOSE: Acute respiratory distress syndrome (ARDS) is a prevalent respiratory condition associated with significant mortality. Current literature on ARDS epidemiology reports a wide range of incidence (7.2-78.9/100,000 population/year), hospital mortality (32-51%), and associated costs ($8476-$547,974). We have analyzed epidemiological trends of mechanically ventilated ARDS (MV-ARDS) in Spain from 2000 to 2022 using the Minimum Basic Data Set (MBDS), focusing on MV-ARDS incidence, associated mortality, and economic impact. METHODS: We conducted a nationwide, population-based retrospective study of all hospitalizations for MV-ARDS in Spanish hospitals-from January 1, 2000 to December 31, 2022-using MBDS records, with an estimated coverage of 99.5%. The study reports MV-ARDS incidence per 100,000 population/year, hospital mortality rate, and mean cost per patient. We also considered the effect of COVID-19 on MV-ARDS epidemiology. RESULTS: We analyzed 93,192 records of patients with a new diagnosis of MV-ARDS during the study period. MV-ARDS incidence ranged from 2.96 to 20.14/100,000 population-years, peaking in 2021. Mortality ranged between 38.0 and 55.0%, showing a declining trend, while the cost per patient increased, stabilizing ~€30,000-€40,000 after reaching a peak of €42,812 in 2011. During the COVID-19 pandemic, hospital stay lengthened (p < 0.001), while hospital mortality decreased (p < 0.001). There was an increased proportion of patients with obesity and diabetes mellitus, with fungal or viral etiologies. CONCLUSION: This is the largest epidemiological study on ARDS in Europe. MV-ARDS incidence has stabilized in recent years, with mortality showing a declining trend. ARDS-related costs have increased nearly fourfold. MBDS data could enhance ARDS understanding and guide future studies.
3. Prognostication and integration of bedside lung ultrasound and computed tomography imaging findings with clinical features to Predict COVID-19 In-hospital mortality and ICU admission.
In 1,230 COVID-19 patients, consolidation on LUS/CT and absent A-lines were associated with mortality, while several imaging patterns predicted ICU admission. Although individual markers performed poorly (AUC <0.65), an integrated CT/LUS-clinical nomogram achieved high mortality prediction accuracy (AUC 87.3%).
Impact: Demonstrates that multimodal integration substantially improves prognostication over imaging alone, supporting risk stratification frameworks in emergency settings.
Clinical Implications: Do not rely on imaging features alone for COVID-19 risk stratification; consider integrated nomograms combining CT/LUS and clinical variables to triage patients on ER arrival.
Key Findings
- Consolidation on BLUS/CT and absence of A-lines were associated with in-hospital mortality.
- Ground-glass opacities, atelectatic bands, mosaic attenuation, crazy paving, and confluent B-lines were associated with ICU admission.
- Individual markers had poor predictive performance (AUC <0.65), whereas the integrated nomogram achieved AUC 87.3% for mortality.
Methodological Strengths
- Large single-center cohort (n=1,230) with systematic evaluation of CT, LUS, and clinical variables.
- Development of an integrated nomogram demonstrating substantial discrimination improvement.
Limitations
- Retrospective single-center design limits generalizability and may introduce selection bias.
- COVID-19-specific model; applicability to non-COVID viral pneumonia or ARDS requires validation.
Future Directions: Prospective multicenter validation and dynamic, serial imaging-clinical integration; extend to broader viral pneumonia/ARDS populations.
INTRODUCTION: Bedside lung ultrasound (LUS) and computed tomography (CT) imaging are valuable modalities in screening and diagnosis of pulmonary diseases. This study aims to investigate the prognostic value of integrating LUS and CT imaging findings with clinical features to predict poor outcomes upon ER admission in COVID-19. METHODS: Patients visiting the study center with clinical presentation and laboratory findings compatible with COVID-19 between April 2020 to January 2022 were considered for this study. Several imaging findings (ground glass opacity, consolidation, atelectatic bands, mosaic attenuation, ARDS pattern, crazy paving, pleural thickening in CT and A-line, comet-tail artifact, confluent B-Line in BLUS, pleural thickening and Consolidation in both modalities) were evaluated, alongside clinical assessments upon admission, to assess their prognostic value. The top radiological, LUS findings, and clinical signs were integrated in a nomogram for predicting mortality. RESULTS: A total of 1230 patients were included in the analyses. Among the findings, consolidation in BLUS and CT imaging, and absence of A-lines were associated with mortality. In addition to these findings, ground-glass opacities, atelectatic band, mosaic attenuation, crazy paving, and confluent B-line were also associated with ICU hospitalization. Although, the prognostic value of individual markers was poor and comparable (AUC < 0.65), the combined use of top clinical and imaging findings in the associated nomogram led to a high accuracy in predicting mortality (Area under curve: 87.3%). CONCLUSIONS: BLUS and CT imaging findings alone provide limited utility in stratifying patients for higher mortality and ICU admission risk and should not be used for risk stratification alone outside the context of each patient and their clinical presentations in suspected COVID-19 patients.